Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Expected to Post Quarterly Sales of $80,000.00
Wall Street analysts predict that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will announce sales of $80,000.00 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with the lowest sales estimate coming in at $20,000.00 and the highest estimate coming in at $100,000.00. Ultragenyx Pharmaceutical posted sales of $110,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 27.3%. The firm is scheduled to report its next earnings results on Monday, November 6th.
On average, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $80,000.00 for the current fiscal year, with estimates ranging from $60,000.00 to $2.36 million. For the next financial year, analysts expect that the firm will report sales of $33.86 million per share, with estimates ranging from $4.55 million to $97.90 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.73) by $0.01. During the same period last year, the business earned ($1.46) earnings per share.
RARE has been the topic of several recent research reports. ValuEngine raised Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. BidaskClub lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Canaccord Genuity set a $98.00 price objective on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Robert W. Baird reissued an “outperform” rating and set a $90.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, April 19th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $84.67.
In related news, VP Theodore Alan Huizenga sold 480 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $57.46, for a total transaction of $27,580.80. Following the completion of the transaction, the vice president now owns 9,366 shares in the company, valued at approximately $538,170.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 9.20% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Tocqueville Asset Management L.P. increased its position in shares of Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 250 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Ultragenyx Pharmaceutical by 68.6% in the second quarter. BNP Paribas Arbitrage SA now owns 14,709 shares of the biopharmaceutical company’s stock valued at $914,000 after buying an additional 5,985 shares during the last quarter. Legal & General Group Plc increased its position in shares of Ultragenyx Pharmaceutical by 17.2% in the second quarter. Legal & General Group Plc now owns 15,082 shares of the biopharmaceutical company’s stock valued at $933,000 after buying an additional 2,212 shares during the last quarter. Alps Advisors Inc. increased its position in shares of Ultragenyx Pharmaceutical by 6.3% in the second quarter. Alps Advisors Inc. now owns 38,165 shares of the biopharmaceutical company’s stock valued at $2,370,000 after buying an additional 2,267 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $1,739,000. Hedge funds and other institutional investors own 95.32% of the company’s stock.
Ultragenyx Pharmaceutical (NASDAQ RARE) opened at 63.30 on Monday. The firm’s market capitalization is $2.69 billion. Ultragenyx Pharmaceutical has a 12 month low of $51.67 and a 12 month high of $91.35. The firm has a 50 day moving average price of $65.11 and a 200-day moving average price of $67.53.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.